Ultragenyx Pharmaceutical/RARE

$53.69

3.8%
-
1D1W1MYTD1YMAX

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Ticker

RARE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Emil Kakkis

Employees

1,276

Headquarters

Novato, United States

RARE Metrics

BasicAdvanced
$4.42B
Market cap
-
P/E ratio
-$8.33
EPS
0.66
Beta
-
Dividend rate

What the Analysts think about RARE

Analyst Ratings

Majority rating from 20 analysts.
Buy

Price Targets

Average projection from 19 analysts.
67.54% upside
High $140.00
Low $48.00
$53.69
Current price
$89.95
Average price target

RARE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-96.7% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$127.3M
29.9%
Net income
$-123.1M
-22.87%
Profit margin
-96.7%
-40.62%

RARE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.15%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$2.33
-$2.25
-$2.23
-$1.52
-
Expected
-$1.98
-$2.07
-$2.08
-$1.62
-$1.76
Surprise
17.89%
8.47%
7.31%
-6.15%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Ultragenyx Pharmaceutical stock

Buy or sell Ultragenyx Pharmaceutical stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing